The Fall Meeting of the DAC Healthcare System Preparedness Learning Laboratory, 15 October 2026
Approved blood-based biomarker tests put earlier, accurate Alzheimer’s diagnosis within reach for millions across the U.S. The bottleneck to patient access is no longer the science; it’s health system adoption. How quickly we expand access across geographies and resource settings is now up to us. Healthcare systems must now prioritize the practical questions and solutions required to speed adoption in line with the scale of the challenge and the urgency felt by every patient and family.
On October 15th, the DAC Healthcare System Preparedness (DAC-SP) Learning Laboratory convened over 600 stakeholders to share lessons from healthcare systems that are pioneering the integration of blood biomarkers (BBMs) into clinical practice. Leaders shared insights from six systems: Icahn School of Medicine at Mount Sinai; Norton Neuroscience Institute; Perelman School of Medicine, University of Pennsylvania; University of Kansas Medical Center; Wake Forest University School of Medicine; and Washington University School of Medicine.
DAC-SP and the Global CEO Initiative on Alzheimer’s Disease (CEOi) continue to develop and share resources that help healthcare system leaders and clinicians across primary and specialty care understand and implement BBM tests and other detection tools. These include the DAC-SP Blueprint, CEOi’s BBM performance standards and educational materials. DAC-SP also plans to release additional open-source tools and resources in early 2027.
Click here to read DAC’s full Call to Action.
SPEAKERS
• Jeffrey Burns, MD (University of Kansas Medical Center)
• Greg Cooper, MD, PhD, MBA, FAAN, FAAPL (Norton Neuroscience Institute)
• Fanny Elahi, MD, PhD (Icahn School of Medicine at Mount Sinai)
• Wheeler Maxwell, MD (University of Pennsylvania Perelman School of Medicine)
• Michelle Mielke, PhD (Wake Forest University School of Medicine)
• Suzanne Schindler, MD, PhD (Washington University School of Medicine in St. Louis)
•Ben Tiede, PhD (The Global CEO Initiative on Alzheimer's Disease)
DAC-SP will continue collaborating with our partners to advance these goals, share findings through our Learning Laboratory, and equip healthcare systems to implement adaptable, proven solutions..